Pulmatrix, Inc. (NASDAQ:PULM) Sees Significant Increase in Short Interest

Pulmatrix, Inc. (NASDAQ:PULM) saw a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 6,500 shares, an increase of 27.5% from the September 30th total of 5,100 shares. Based on an average daily trading volume, of 11,300 shares, the short-interest ratio is currently 0.6 days. Currently, 0.2% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, StockNews.com started coverage on Pulmatrix in a report on Friday, October 25th. They set a “hold” rating on the stock.

Pulmatrix Stock Performance

Shares of PULM remained flat at $2.18 during trading hours on Wednesday. 31,250 shares of the stock traded hands, compared to its average volume of 13,565. The stock has a 50 day moving average price of $2.06 and a two-hundred day moving average price of $2.03. The stock has a market capitalization of $7.96 million, a price-to-earnings ratio of -0.89 and a beta of 1.00. Pulmatrix has a 52 week low of $1.55 and a 52 week high of $2.75.

Pulmatrix (NASDAQ:PULM) last issued its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter. The firm had revenue of $1.55 million for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.